Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Bridgewater

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Oncology|August 26, 1999
Management of non-epithelial ovarian tumoursJ A Bridgewater, G J Rustin
British Medical Bulletin|July 1, 1995
Biological response modifiers in melanomaJ A Bridgewater, M E Gore
Gynecologic Oncology|September 23, 1997
Pseudo-Meigs' syndrome secondary to an ovarian germ cell tumorJ A Bridgewater, G J Rustin
Postgraduate Medical Journal|January 1, 1993
Malignant phaeochromocytoma and hypercalcaemiaJ A Bridgewater, W A Ratcliffe, N J Bundred, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Intracranial germ cell tumours presenting with hypopituitarism. Successful treatment with chemotherapy aloneJ A Bridgewater, R L Souhami, J Allgrove, et al.
Human Gene Therapy|April 10, 1997
The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metaboliteJ A Bridgewater, R J Knox, J D Pitts, et al.
Melanoma Research|August 1, 1995
The histological and immunohistochemical changes in the skin of patients with melanoma who develop changes in skin pigmentation following immunotherapyJ Salter, K MacLennan, J A Bridgewater, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 1995
Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954J A Bridgewater, C J Springer, R J Knox, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxelJ A Bridgewater, A E Nelstrop, G J Rustin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2024
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profilingL Goyal, D DiToro, A Hollebecque, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Oncology|August 26, 1999
Management of non-epithelial ovarian tumoursJ A Bridgewater, G J Rustin
British Medical Bulletin|July 1, 1995
Biological response modifiers in melanomaJ A Bridgewater, M E Gore
Gynecologic Oncology|September 23, 1997
Pseudo-Meigs' syndrome secondary to an ovarian germ cell tumorJ A Bridgewater, G J Rustin
Postgraduate Medical Journal|January 1, 1993
Malignant phaeochromocytoma and hypercalcaemiaJ A Bridgewater, W A Ratcliffe, N J Bundred, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Intracranial germ cell tumours presenting with hypopituitarism. Successful treatment with chemotherapy aloneJ A Bridgewater, R L Souhami, J Allgrove, et al.
Human Gene Therapy|April 10, 1997
The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metaboliteJ A Bridgewater, R J Knox, J D Pitts, et al.
Melanoma Research|August 1, 1995
The histological and immunohistochemical changes in the skin of patients with melanoma who develop changes in skin pigmentation following immunotherapyJ Salter, K MacLennan, J A Bridgewater, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 1995
Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954J A Bridgewater, C J Springer, R J Knox, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxelJ A Bridgewater, A E Nelstrop, G J Rustin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2024
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profilingL Goyal, D DiToro, A Hollebecque, et al.
Pageof 2